- United States
- /
- Insurance
- /
- NasdaqGM:TRUP
A Piece Of The Puzzle Missing From Trupanion, Inc.'s (NASDAQ:TRUP) 27% Share Price Climb
Trupanion, Inc. (NASDAQ:TRUP) shares have continued their recent momentum with a 27% gain in the last month alone. The last 30 days bring the annual gain to a very sharp 28%.
Even after such a large jump in price, you could still be forgiven for feeling indifferent about Trupanion's P/S ratio of 1.4x, since the median price-to-sales (or "P/S") ratio for the Insurance industry in the United States is also close to 1.1x. While this might not raise any eyebrows, if the P/S ratio is not justified investors could be missing out on a potential opportunity or ignoring looming disappointment.
Check out our latest analysis for Trupanion
How Has Trupanion Performed Recently?
Trupanion certainly has been doing a good job lately as it's been growing revenue more than most other companies. It might be that many expect the strong revenue performance to wane, which has kept the P/S ratio from rising. If the company manages to stay the course, then investors should be rewarded with a share price that matches its revenue figures.
Want the full picture on analyst estimates for the company? Then our free report on Trupanion will help you uncover what's on the horizon.Is There Some Revenue Growth Forecasted For Trupanion?
Trupanion's P/S ratio would be typical for a company that's only expected to deliver moderate growth, and importantly, perform in line with the industry.
If we review the last year of revenue growth, the company posted a terrific increase of 21%. Pleasingly, revenue has also lifted 112% in aggregate from three years ago, thanks to the last 12 months of growth. Accordingly, shareholders would have definitely welcomed those medium-term rates of revenue growth.
Turning to the outlook, the next three years should generate growth of 9.5% per year as estimated by the eight analysts watching the company. That's shaping up to be materially higher than the 4.3% per annum growth forecast for the broader industry.
With this in consideration, we find it intriguing that Trupanion's P/S is closely matching its industry peers. It may be that most investors aren't convinced the company can achieve future growth expectations.
What We Can Learn From Trupanion's P/S?
Trupanion's stock has a lot of momentum behind it lately, which has brought its P/S level with the rest of the industry. Generally, our preference is to limit the use of the price-to-sales ratio to establishing what the market thinks about the overall health of a company.
Looking at Trupanion's analyst forecasts revealed that its superior revenue outlook isn't giving the boost to its P/S that we would've expected. There could be some risks that the market is pricing in, which is preventing the P/S ratio from matching the positive outlook. It appears some are indeed anticipating revenue instability, because these conditions should normally provide a boost to the share price.
It is also worth noting that we have found 1 warning sign for Trupanion that you need to take into consideration.
If these risks are making you reconsider your opinion on Trupanion, explore our interactive list of high quality stocks to get an idea of what else is out there.
Valuation is complex, but we're here to simplify it.
Discover if Trupanion might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About NasdaqGM:TRUP
Trupanion
Provides medical insurance for cats and dogs on a monthly subscription basis in the United States, Canada, Continental Europe, and Australia.
Excellent balance sheet with reasonable growth potential.